{"id":"W4295820891","doi":"10.1016/j.annonc.2022.07.939","title":"813P Time to development of central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with vemurafenib (V) + cobimetinib (C): Updated results from the phase III IMspire150 study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Vemurafenib; Placebo; Internal medicine; Oncology; Pembrolizumab; Pathology; Cancer; Immunotherapy; Metastatic melanoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008128533,0.0005671649,0.001173511,0.0001799926,0.0001492799,0.0007258858,0.0002883284,0.0005011148,0.003899796],"category_scores_gemma":[0.001208363,0.0002204684,0.001695182,0.000303145,0.0001400954,0.0005496466,0.0002457495,0.001524083,0.0006270178],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004326641,"about_ca_system_score_gemma":0.0004150067,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008265292,"about_ca_topic_score_gemma":0.002138155,"domain_scores_codex":[0.9997409,0.00007564091,0.00002122575,0.00006540559,0.00004854865,0.00004828546],"domain_scores_gemma":[0.9994343,0.0001685184,0.0002145762,0.00003541273,0.0000587797,0.00008842774],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4764213,0.001784281,0.06832365,0.003296852,0.0143225,0.0004830539,0.0001090973,0.005626694,0.02032839,0.0007479648,0.02292486,0.3856314],"study_design_scores_gemma":[0.1040985,0.09883485,0.6744271,0.0007748222,0.03246892,0.002464905,0.0002278428,0.0062684,0.01382687,0.003674248,0.06273394,0.0001995134],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9399251,0.03196275,0.0021613,0.001246556,0.0007343924,0.0002568591,0.01326639,0.0002156228,0.0102311],"genre_scores_gemma":[0.9780628,0.005997297,0.0007831119,0.001003508,0.0002710208,0.0002748457,0.008727709,0.00004806034,0.004831717],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003899796,"threshold_uncertainty_score":0.01304609,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03804869258544963,"score_gpt":0.3045034102998207,"score_spread":0.2664547177143711,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}